Sinew Pharma Inc.
Sinew Pharma Inc., a biopharmaceutical company, focuses on the research, development, and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases. The company's products include SNP-610 drug, which is in Phase IIa clinical trial and SNP-630 drug, which is in Phase II clinical trial for treating patients with non-alcoholic steatohepatitis in Taiwan. It is also… Read more
Market Cap & Net Worth: Sinew Pharma Inc. (6634)
Sinew Pharma Inc. (TWO:6634) has a market capitalization of $71.75 Million (NT$2.37 Billion) as of March 18, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #21708 globally and #1204 in its home market, demonstrating a -9.39% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sinew Pharma Inc.'s stock price NT$33.30 by its total outstanding shares 71292610 (71.29 Million).
Sinew Pharma Inc. Market Cap History: 2026 to 2026
Sinew Pharma Inc.'s market capitalization history from 2026 to 2026. Data shows growth from $71.75 Million to $71.75 Million (0.00% CAGR).
Sinew Pharma Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sinew Pharma Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 6634 by Market Capitalization
Companies near Sinew Pharma Inc. in the global market cap rankings as of March 18, 2026.
Key companies related to Sinew Pharma Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Sinew Pharma Inc. Historical Marketcap From 2026 to 2026
Between 2026 and today, Sinew Pharma Inc.'s market cap moved from $71.75 Million to $ 71.75 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$71.75 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Sinew Pharma Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $71.75 Million USD |
| MoneyControl | $71.75 Million USD |
| MarketWatch | $71.75 Million USD |
| marketcap.company | $71.75 Million USD |
| Reuters | $71.75 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.